Medpace Holdings (MEDP) EBIT Margin (2015 - 2026)

Medpace Holdings (MEDP) has reported EBIT Margin for 12 consecutive years, with 20.76% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT Margin fell 18.0% year-over-year to 20.76%; the trailing twelve-month figure through Jun 2026 stood at 20.97% (down 43.0% YoY), and the FY2025 full-year result was 21.14%, down 5.0% from the prior year.
• EBIT Margin improved to 20.76% in Q2 2026 per MEDP's latest filing, from 20.03% in the prior quarter.
• Across five years, EBIT Margin topped out at 23.37% in Q4 2024 and bottomed at 17.01% in Q2 2023.
• Historically, EBIT Margin has averaged 19.87% across 5 years, with a median of 20.15% in 2022.
• The sharpest annual moves came in 2023 and 2024: EBIT Margin slumped 304 bps in 2023, then jumped 585 bps in 2024.
• Over 5 years, EBIT Margin stood at 19.39% in 2022, then dropped by 10 bps to 17.52% in 2023, then soared by 33 bps to 23.37% in 2024, then retreated by 7 bps to 21.63% in 2025, then declined by 4 bps to 20.76% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 20.76%, 20.03%, and 21.63% for Q2 2026, Q1 2026, and Q4 2025 respectively.